ArticleAntimicrobial agents and chemotherapy2015
Assessing primary and secondary resistance to clarithromycin and amikacin in infections due to Mycobacterium avium complex.
Open access · bronzeAbstract readLetter
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Omadacycline as a drug candidate for Mycobacterium avium infections: in vitro insights on single and combination therapies.The Journal of antimicrobial chemotherapy · 2026Article
- Review of the Canadian Nontuberculous Mycobacterial Disease Landscape-Challenges and Opportunities.Tropical medicine and infectious disease · 2025Review
- The N-Terminal Extension of theAntibiotics (Basel, Switzerland) · 2025Article
- Risk factors, molecular analysis and treatment outcomes of amikacin-resistantERJ open research · 2025Article
- Drug susceptibility profiles ofJournal of medical microbiology · 2025Article
- Effects of Amikacin Liposome Inhalation Suspension and Amikacin Resistance Development in Patients With RefractoryOpen forum infectious diseases · 2025Article
- Characterisation and antimicrobial susceptibility pattern of non-tuberculous mycobacteria.Southern African journal of infectious diseases · 2024Article
- MGIT-seq for the Identification of Nontuberculous Mycobacteria and Drug Resistance: a Prospective Study.Journal of clinical microbiology · 2023Article
- Antimicrobial Susceptibility of Clinical and Environmental Mycobacterium chimaera Isolates.Antimicrobial agents and chemotherapy · 2019Article
- GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance.Journal of clinical microbiology · 2019Article
- Insights on the relationship between structure vs. toxicological activity of antibacterial rhodamine-labelled 3-hydroxy-4-pyridinone iron(III) chelators in HepG2 cells.Interdisciplinary toxicology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Aurélie RenvoiséCentre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Paris, France AP-HP, Hôpital Pitié-Salpêtrière, Bactériologie-Hygiène, Paris, France Sorbonne Universités, UPMC Université de Paris 06, U1135, Centre for Immunology and Microbial Infections, Team 13, Paris, France INSERM, U1135, Centre for Immunology and Microbial Infections, Team 13, Paris, France.
Florence BrossierCentre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Paris, France AP-HP, Hôpital Pitié-Salpêtrière, Bactériologie-Hygiène, Paris, France Sorbonne Universités, UPMC Université de Paris 06, U1135, Centre for Immunology and Microbial Infections, Team 13, Paris, France INSERM, U1135, Centre for Immunology and Microbial Infections, Team 13, Paris, France.
Eve GalatiCentre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Paris, France AP-HP, Hôpital Pitié-Salpêtrière, Bactériologie-Hygiène, Paris, France.
Nicolas VezirisCentre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Paris, France AP-HP, Hôpital Pitié-Salpêtrière, Bactériologie-Hygiène, Paris, France Sorbonne Universités, UPMC Université de Paris 06, U1135, Centre for Immunology and Microbial Infections, Team 13, Paris, France INSERM, U1135, Centre for Immunology and Microbial Infections, Team 13, Paris, France.
Wladimir SougakoffCentre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Paris, France AP-HP, Hôpital Pitié-Salpêtrière, Bactériologie-Hygiène, Paris, France Sorbonne Universités, UPMC Université de Paris 06, U1135, Centre for Immunology and Microbial Infections, Team 13, Paris, France INSERM, U1135, Centre for Immunology and Microbial Infections, Team 13, Paris, France.
Alexandra AubryCentre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Paris, France AP-HP, Hôpital Pitié-Salpêtrière, Bactériologie-Hygiène, Paris, France Sorbonne Universités, UPMC Université de Paris 06, U1135, Centre for Immunology and Microbial Infections, Team 13, Paris, France INSERM, U1135, Centre for Immunology and Microbial Infections, Team 13, Paris, France.
Jérôme RobertCentre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Paris, France AP-HP, Hôpital Pitié-Salpêtrière, Bactériologie-Hygiène, Paris, France Sorbonne Universités, UPMC Université de Paris 06, U1135, Centre for Immunology and Microbial Infections, Team 13, Paris, France INSERM, U1135, Centre for Immunology and Microbial Infections, Team 13, Paris, France.
Emmanuelle CambauCentre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Paris, France APHP, Hôpitaux Universitaires Lariboisière-Saint Louis, Service de Bactériologie, Paris, France Université Paris Diderot, Sorbonne Paris Cité, Inserm IAME UMR 1137, Paris, France.
Vincent JarlierCentre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Paris, France AP-HP, Hôpital Pitié-Salpêtrière, Bactériologie-Hygiène, Paris, France Sorbonne Universités, UPMC Université de Paris 06, U1135, Centre for Immunology and Microbial Infections, Team 13, Paris, France INSERM, U1135, Centre for Immunology and Microbial Infections, Team 13, Paris, France.
Christine BernardCentre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Paris, France AP-HP, Hôpital Pitié-Salpêtrière, Bactériologie-Hygiène, Paris, France Sorbonne Universités, UPMC Université de Paris 06, U1135, Centre for Immunology and Microbial Infections, Team 13, Paris, France INSERM, U1135, Centre for Immunology and Microbial Infections, Team 13, Paris, France christine.bernard@psl.aphp.fr.
Inserm · FRSorbonne Université · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AmikacinAnti-Bacterial AgentsClarithromycinDrug Resistance, BacterialMicrobial Sensitivity TestsMycobacterium avium ComplexAmikacinAnti-Bacterial AgentsClarithromycin
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.